Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

of a Phase 3 registration trial with perifosine in refractory advanced colorectal cancer by Keryx. - April 15, 2010: Positive Scientific Advice from the EMA for the Phase 3 program with perifosine in multiple myeloma. Data from ongoing Phase 3 study, sponsored by Keryx, can be used to register perifosine in multiple myeloma in Europe. - April 20, 2010: Presentations of preclinical data on Erk inhibitor, AEZS-131, and Erk/PI3K dual inhibitor, AEZS-132, as well as preclinical data from a study sponsored by the National Institutes of Health with perifosine in oncology at the American Association for Cancer Research Annual Meeting in Washington, D.C. - April 20, 2010: Completion of a $15.0 million registered direct offering with certain institutional investors. - April, 23, 2010: Company regained compliance with Nasdaq's minimum bid price listing requirement. - May 6, 2010: Company receives orphan-drug designation from the FDA for AEZS-108 in ovarian cancer. - May 12, 2010: FDA approves the Company's Investigational New Drug (IND) application for AEZS-108 in LHRH-receptor positive urothelial (bladder) cancer.

Juergen Engel, Ph.D., Aeterna Zentaris' President and Chief Executive Officer commented, "This has been a very exciting quarter as we made great strides in the development of our lead oncology compound, perifosine, now in Phase 3 registration trials for multiple myeloma and refractory advanced colorectal cancer. Furthermore, the different designations recently granted by the FDA in both indications and the EMA's positive Scientific Advice for multiple myeloma, will accelerate as well as facilitate the future review and marketing authorization processes in North America and Europe."


SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ... capital and general corporate purposes. Under ...
(Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ... forecasts of the revenue and share analysis. ...
(Date:12/24/2014)... Boston, MA (PRWEB) December 23, 2014 ... presentation, Dr. James L. Sherley, director of the Adult ... attention on an often overlooked and under appreciated unique ... “Asymmetric Self-Renewal by Distributed Stem Cells: Misunderstood in the ... his message to congress participants. He gave the ...
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... PRINCETON, N.J., July 8 DOR BioPharma, Inc. ... a late-stage biopharmaceutical company, announced today that it ... Lipid Polymer Micelle (LPM(TM)) technology for the improved ... EP 1460992, entitled "Stabilized Reverse Micelle Compositions and ...
... of Wisconsin-Madison biomedical engineer and colleagues have developed a ... could spare some women with increased breast cancer risk ... biopsy of a questionable lump or lesion. The ... classifying a lesion as malignant or benign. ...
... advanced energy research , , MONTREAL, July 7 ... technology company, today announced that it will jointly form ... Edmonton and the Alberta Energy Research Institute (AERI). , ... demonstration of novel catalytic conversion processes to produce advanced ...
Cached Biology Technology:DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 2DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 3DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 4DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology 5New MRI technique could mean fewer breast biopsies in high-risk women 2Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada 2Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada 3
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the addition of the "The Global ... their offering. ... an overview of the global digital media ... control and monitor piracy by securely and ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Service Weekly PressPac with news from ACS, 34 peer-reviewed journals ... journal or the American Chemical Society as the source for ... Clothing to crow about: Chicken feather suits and dresses, ... up in warm, cozy sweats made of chicken feathers or ...
... technologies that make it easier to sequence the human ... Center have identified a series of genes that become ... These recurrent gene fusions are thought to be the ... The gene fusions discovered could potentially serve as a ...
... Researchers at Mayo Clinic have discovered the first ... In the Jan. 11 online edition of Nature ... genome-wide association study of patients with Alzheimer,s disease. The ... a variant in the PCDH11X gene, found on the ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Jan. 7, 2009 2American Chemical Society's Weekly PressPac -- Jan. 7, 2009 3American Chemical Society's Weekly PressPac -- Jan. 7, 2009 4American Chemical Society's Weekly PressPac -- Jan. 7, 2009 5American Chemical Society's Weekly PressPac -- Jan. 7, 2009 6American Chemical Society's Weekly PressPac -- Jan. 7, 2009 7American Chemical Society's Weekly PressPac -- Jan. 7, 2009 8American Chemical Society's Weekly PressPac -- Jan. 7, 2009 9U-M researchers discover new genes that fuse in cancer 2Mayo: Variants in gene on X chromosome associated with increased susceptibility to Alzheimer's 2Mayo: Variants in gene on X chromosome associated with increased susceptibility to Alzheimer's 3
... nmol (individual) with sequence siTrio siRNA ... to your target gene of interestis our most ... more than 75% knockdown of your target gene ... for transfection and confirmation of optimal transfection with ...
The Bio-Plex Manager version 3.0 to 4.0 workstation software upgrade kit is used to upgrade existing Bio-Plex Manager version 3.0 software to version 4.0 security edition software....
... rigid macroporous hydrophilic media. The rigid polymer ... pressures, while the macroporous beads enhance access ... reduces nonspecific binding. Macro-Prep High Q support ... very high flow rates and resolution. It ...
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
Biology Products: